Results 51 to 60 of about 33,952 (165)

Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies

Cell Reports Medicine
Summary: IMCnyeso, an immune mobilizing monoclonal T cell receptor against cancer (ImmTAC) bispecific (New York esophageal squamous cell carcinoma [NY-ESO]×CD3) T cell engager, targets an NY-ESO-1/L-antigen family member-1 isoform A (LAGE-1A) peptide ...
Juanita S. Lopez, Mohammed Milhem, Marcus O. Butler, Fiona Thistlethwaite, Brian A. Van Tine, Sandra P. D’Angelo, Melissa L. Johnson, Takami Sato, Hendrik-Tobias Arkenau, Ramakrishna Edukulla, Jason Wustner, Shannon Marshall, Jordi Rodon   +12 more
doaj   +1 more source

Modular design of bi- and multi-specific knob domain fusions

Frontiers in Immunology
IntroductionThe therapeutic potential of bispecific antibodies is becoming widely recognised, with over a hundred formats already described. For many applications, enhanced tissue penetration is sought, so bispecifics with low molecular weight may offer ...
Mikhail Kuravsky, Glyn F. Gibbons, Callum Joyce, Anthony Scott-Tucker, Alex Macpherson, Alastair D. G. Lawson   +5 more
doaj   +1 more source

The evolution of bispecific antibodies [PDF]

Expert Opinion on Biological Therapy, 2022
openaire   +2 more sources

Novel Bispecific T-Cell Engagers for the Treatment of Relapsed B Cell Non-Hodgkin Lymphomas: Current Knowledge and Treatment Considerations

Patient Preference and Adherence
Ben Varon,1 Netanel A Horowitz,1,2 Hazim Khatib1 1Department of Hematology and Bone Marrow Transplantation, Rambam Healthcare Campus, Haifa 3109601, Israel; 2Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3109601 ...
Varon B, Horowitz NA, Khatib H
doaj  

Discovery and development of a bispecific antibody for the treatment of hemophilia. [PDF]

Proc Natl Acad Sci U S A
Pao W.
europepmc   +1 more source

Bispecific antibodies in gastrointestinal cancers: current applications and future perspectives. [PDF]

Front Oncol
Ismail M, Al-Gizey N, Al-Najjar E, Alabed Z, Mustafa N, Hamdaneh Y, Esmail A.   +6 more
europepmc   +1 more source

Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors. [PDF]

J Hematol Oncol
Lou J, Lyu Y.
europepmc   +1 more source

Kunihiro Hattori, Tomoyuki Igawa, and Takehisa Kitazawa share Lasker Award honors for revolutionary hemophilia A therapy. [PDF]

J Clin Invest
Flaumenhaft R.
europepmc   +1 more source

Expression of Concern for EGFR- and HER3-targeted bispecific antibody-drug conjugate demonstrates antitumor activity in metastatic castration-resistant prostate cancer. [PDF]

J Clin Invest
Fang B, Li X, Lu Y, Ma W, Gan H, Zhang T, Liu Q, Wang B, Wang Z, Zhu Y, Zhu H, Xiao S, Bian X, Wei G, Ye D, Zhu Y.   +15 more
europepmc   +1 more source

Bispecific antibody-drug conjugates in cancer: therapeutic-window determinants, tumour-immune interactions, and clinical translation. [PDF]

Front Immunol
Li Y, Li Y, Huang R, San ZQ, Ye JF.
europepmc   +1 more source